(1.17%) 5 123.62 points
(1.14%) 38 663 points
(1.90%) 16 142 points
(-0.62%) $78.46
(4.91%) $2.14
(-0.22%) $2 304.50
(-0.48%) $26.70
(0.24%) $964.95
(-0.36%) $0.929
(-1.24%) $10.85
(-0.08%) $0.797
(0.34%) $91.44
0.44% HKD 18.12
Live Chart Being Loaded With Signals
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally...
Stats | |
---|---|
Volumen de hoy | 977 288 |
Volumen promedio | 4.41M |
Capitalización de mercado | 11.31B |
EPS | HKD0 ( 2023-08-17 ) |
Last Dividend | HKD0.390 ( 2023-06-02 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 9.74 |
ATR14 | HKD0.00800 (0.04%) |
Volumen Correlación
SciClone Pharmaceuticals, Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
SciClone Pharmaceuticals, Correlación - Moneda/Commodity
SciClone Pharmaceuticals, Finanzas
Annual | 2023 |
Ingresos: | HKD3.16B |
Beneficio Bruto: | HKD2.36B (74.67 %) |
EPS: | HKD1.830 |
FY | 2023 |
Ingresos: | HKD3.16B |
Beneficio Bruto: | HKD2.36B (74.67 %) |
EPS: | HKD1.830 |
FY | 2022 |
Ingresos: | HKD2.75B |
Beneficio Bruto: | HKD2.07B (75.30 %) |
EPS: | HKD1.270 |
FY | 2021 |
Ingresos: | HKD2.52B |
Beneficio Bruto: | HKD1.93B (76.75 %) |
EPS: | HKD1.420 |
Financial Reports:
No articles found.
SciClone Pharmaceuticals, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.390 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.350 | 2022-05-27 |
Last Dividend | HKD0.390 | 2023-06-02 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | HKD0.740 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.31 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.58 | |
Div. Directional Score | 9.28 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2381.HK | Ex Dividend Junior | 2023-09-07 | Annually | 0 | 0.00% | |
1361.HK | Ex Dividend Knight | 2023-08-28 | Annually | 0 | 0.00% | |
0405.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
6812.HK | Ex Dividend Junior | 2023-08-04 | Sporadic | 0 | 0.00% | |
1916.HK | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
0945.HK | Ex Dividend King | 2023-08-22 | Quarterly | 0 | 0.00% | |
0064.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
3300.HK | No Dividend Player | 2023-08-02 | Sporadic | 0 | 0.00% | |
1513.HK | Ex Dividend Knight | 2023-07-04 | Annually | 0 | 0.00% | |
0558.HK | Ex Dividend Junior | 2023-09-12 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.356 | 1.500 | 2.89 | 4.33 | [0 - 0.5] |
returnOnAssetsTTM | 0.280 | 1.200 | 0.651 | 0.782 | [0 - 0.3] |
returnOnEquityTTM | 0.369 | 1.500 | 7.01 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.192 | -1.000 | 8.08 | -8.08 | [0 - 1] |
currentRatioTTM | 4.94 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.43 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.59 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00821 | -1.500 | 9.86 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 35.54 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.894 | 2.00 | 9.70 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.893 | 2.00 | 9.55 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0101 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.747 | 1.000 | 0.889 | 0.889 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.382 | 1.000 | 4.36 | 4.36 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 17.66 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.789 | 0.800 | 8.07 | 6.46 | [0.5 - 2] |
Total Score | 11.99 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 9.68 | 1.000 | 9.12 | 0 | [1 - 100] |
returnOnEquityTTM | 0.369 | 2.50 | 8.08 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.893 | 2.00 | 9.70 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.33 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.894 | 2.00 | 9.70 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.192 | 1.500 | 8.08 | -8.08 | [0 - 1] |
pegRatioTTM | 0.374 | 1.500 | -0.838 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.184 | 1.000 | 7.91 | 0 | [0.1 - 0.5] |
Total Score | 6.58 |
SciClone Pharmaceuticals,
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhance. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma; and Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome. The company's pipeline products comprise Vibativ, a bactericidal, once-daily, injectable lipoglycopeptide antibiotic for the treatment of adult patients with hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/ leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic which treats solid tumors; PEN-866, a HSP90-binding miniature drug conjugate; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico